Developing RNA-Targeted Cures for Cancer

iNanoRNA Therapeutics is a biopharmaceutical company developing first in class transformative RNA-targeted life-changing oncology therapies.

Our Mission

About Us

iNanoRNA Therapeutics was founded in 2024. The company was established based on over a decade of innovative research and development on microRNA and cancer from Professor Jingfang Ju of the Renaissance School of Medicine, Stony Brook University.

We strive to push the boundary of science and medicine with a focus on innovative medicine to provide value to patients. iNanoRNA Therapeutics has several patented platform technologies to develop microRNA mimics to target resistant cancer stem-like cells. Our unique modifications of microRNA enhance stability, efficacy, and ease of delivery.

Our Science

iNanoRNA Therapeutics has developed a clinically validated first-in-class multimodal tumor-targeting RNAi-small molecule platform, designed to cure naïve and refractory solid and liquid cancers by overcoming tumor heterogeneity and therapy resistance.

Our R&D pipeline is focused on Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Gastric Cancer, and Acute Myeloid Leukemia (AML), with secondary indications in Ovarian, Pancreas, and Triple Negative Breast Cancer (TNBC).

Our scientific translational rationale is based on over 20 years of research on the mechanisms of cancer resistance mediated by the epigenetic regulation of a small class of non-coding RNA, known as microRNA (miRNA). Our founding team have discovered a panel of miRNAs with tumor suppressive functions in across multiple cancer typs. The reduction of expression of tumor suppressor miRNAs directly impact cancer cell growth, cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition. All of which contribute to anticancer therapeutic resistance.

Pipeline

News

Coming Soon…

Leadership

Team

  • ANTON XAVIER, BSc, MSc, MBA

    CEO

    Anton Xavier is an Oncology Biopharma BD&L and R&D executive with over 20 years of buy & sell side experience in investments, licensing, strategic partnerships, and search and evaluation (S&E). With prior leadership roles at the NY State Center for Biotechnology, Pfizer Oncology, and the Finance Industry, Anton has led various efforts focused on the commercialization of targeted therapeutic assets. Prior to industry, Anton’s academic experiences had impacted a wide field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs.

  • JINGFANG JU, Ph.D.

    Scientific Co-founder

    Dr. Jingfang Ju is a Professor at the Renaissance School of Medicine, Stony Brook University. He is the founder of Curamir Therapeutics Inc. and the inventor of a miRNA-based cancer therapeutic platform technology, holding several patents in this area. Dr. Ju has over twenty years of research experience focusing on non-coding microRNA in cancer, particularly resistance mechanisms. He has published more than 100 academic articles. In addition to leading an NIH/NCI-funded translational research laboratory, he was also awarded the Glaxo Wellcome Oncology Clinical Research Scholar Award. He earned his B.S. in Chemical Engineering from Northeastern University in China, a Ph.D. in molecular biology and biochemistry from the University of Southern California, and completed a post-doctoral fellowship in molecular pharmacology at Yale University.

  • YUPO MA, MD. Ph.D.

    Co-Founder & Chief Clinical Advisor

    Dr. Yupo Ma is a professor at Stony Brook University. He has 30+ years of cancer immunotherapy research and clinical development. Founder of iCell Gene Therapeutics.

  • GA-RAM HWANG, Ph.D.

    R&D Director

    Dr. Ga-Ram Hwang was trained with Dr. Ju in miRNA cancer research. Dr. Hwang developed Gem-modified miRNA for lung cancer and pancreatic cancer treatment. Dr. Hwang has extensive experience and expertise in miRNA based drug development using both in vitro and in vivo models.

  • NEIL S. LEVINBOOK

    General Counsel

  • JAMES F. HARRINGTON

    Patent Lawyer

Whether you have a question or an inquiry, feel free to reach out.

Get in Touch